Table 1.
The clinical background of patients (n=65).
| Characteristics | Number of patients (%) |
|---|---|
| Age(years) | |
| <60 | 40 (61.5) |
| ≥60 | 25 (38.5) |
| Primary tumor | |
| T1 | 19 (29.2) |
| T2 | 38 (58.5) |
| T3 | 8 (12.3) |
| Molecular subtype | |
| TNBC | 16 (24.6) |
| Non-TNBC | 49 (75.4) |
| Menopause status | |
| Premenopausal | 38 (58.5) |
| Postmenopausal | 27 (41.5) |
| Regional lymph nodes* | |
| N0 | 35 (53.8) |
| N1 | 14 (21.5) |
| N2 | 10 (15.4) |
| N3 | 6 (9.3) |
| Stage* | |
| I | 9 (13.8) |
| II | 32 (49.2) |
| IIII | 24 (36.9) |
| Distant metastasis* | |
| M0 | 63 (96.9) |
| M1 | 2 (3.1) |
| Vascular invasion* | |
| Absent | 53 (81.5) |
| Present | 12 (18.5) |
| Lymphatic invasion* | |
| Absent | 48 (73.8) |
| Present | 17 (26.2) |
| HER2 overexpression/amplification | |
| Negative | 54 (83.1) |
| Positive | 11 (16.9) |
| Estrogen receptor expression | |
| Negative | 25 (38.5) |
| Positive | 40 (61.5) |
*
According to cancer grading system of AJCC.